全文获取类型
收费全文 | 21249篇 |
免费 | 2078篇 |
国内免费 | 300篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 1136篇 |
妇产科学 | 426篇 |
基础医学 | 2015篇 |
口腔科学 | 166篇 |
临床医学 | 1627篇 |
内科学 | 2552篇 |
皮肤病学 | 256篇 |
神经病学 | 1051篇 |
特种医学 | 2089篇 |
外国民族医学 | 9篇 |
外科学 | 1551篇 |
综合类 | 2027篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 3309篇 |
眼科学 | 68篇 |
药学 | 2788篇 |
20篇 | |
中国医学 | 484篇 |
肿瘤学 | 1961篇 |
出版年
2024年 | 31篇 |
2023年 | 374篇 |
2022年 | 729篇 |
2021年 | 934篇 |
2020年 | 940篇 |
2019年 | 896篇 |
2018年 | 956篇 |
2017年 | 819篇 |
2016年 | 797篇 |
2015年 | 731篇 |
2014年 | 1599篇 |
2013年 | 1688篇 |
2012年 | 1205篇 |
2011年 | 1415篇 |
2010年 | 1106篇 |
2009年 | 1102篇 |
2008年 | 1063篇 |
2007年 | 992篇 |
2006年 | 770篇 |
2005年 | 653篇 |
2004年 | 550篇 |
2003年 | 445篇 |
2002年 | 389篇 |
2001年 | 337篇 |
2000年 | 305篇 |
1999年 | 243篇 |
1998年 | 203篇 |
1997年 | 183篇 |
1996年 | 157篇 |
1995年 | 143篇 |
1994年 | 149篇 |
1993年 | 141篇 |
1992年 | 111篇 |
1991年 | 118篇 |
1990年 | 97篇 |
1989年 | 99篇 |
1988年 | 85篇 |
1987年 | 92篇 |
1986年 | 75篇 |
1985年 | 137篇 |
1984年 | 109篇 |
1983年 | 72篇 |
1982年 | 80篇 |
1981年 | 78篇 |
1980年 | 86篇 |
1979年 | 77篇 |
1978年 | 53篇 |
1977年 | 39篇 |
1976年 | 40篇 |
1973年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 968 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
《Molecular therapy》2022,30(5):1885-1896
- Download : Download high-res image (90KB)
- Download : Download full-size image
3.
4.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
5.
6.
《Obesity research & clinical practice》2020,14(2):158-163
Although an inverse relationship between body mass index (BMI) and baroreflex sensitivity (BRS) was found, the effect of waist circumference (WC) on BRS is still inconclusive. The contradictory results of previous studies may be related to the heterogeneity and relatively small sample size of the subjects examined. The aim of this population-based study was to investigate whether the influence of increased WC is more detrimental to BRS than BMI. A total of 760 community dwellers were recruited and they were classified into Q1 (n = 189), Q2 (n = 183), Q3 (n = 192) and Q4 (n = 196) groups, based on WC quartiles. Spontaneous BRS was determined by spectral α coefficient method. Valsalva ratio was the longest RR interval after release of Valsalva maneuver divided by the shortest RR interval during maneuver. Cardiac autonomic function was calculated by power spectrum of heart rate in low and high frequency (LF, 0.04–0.15 Hz; HF, 0.15–0.40 Hz), and LF/HF ratio in supine position for five minutes. There were significant differences in spontaneous BRS and Valsalva ratio among different WC groups. In multivariate analysis, obesity was inversely associated with spontaneous BRS and Valsalva ratio. However, these inverse relationships became insignificant after further adjustment for WC quartiles. In contrast, Q4 vs. Q1, Q3 vs. Q1 and Q2 vs. Q1 of WC were inversely related to spontaneous BRS. Q4 vs. Q1 and Q3 vs. Q1 of WC were negatively associated with the Valsalva ratio. In conclusion, increased and even high-normal WC had a stronger adverse effect on BRS than BMI, independent of cardio-metabolic risk factors. 相似文献
7.
8.
目的:探讨3D-CRT 低剂量区 V5体积的大小对非小细胞肺癌患者肺功能的影响。方法:收集我院肿瘤科2014年4月~2015年10月收治的46例首次行三维适形放射治疗且顺利完成治疗的非小细胞肺癌患者,对每例患者分别在治疗前以及治疗后的1、3个月进行肺功能检测,分析3D-CRT 低剂量区 V5体积的大小与肺功能变化之间的关系。结果:放疗后1个月的 FEV1%、FVC%值明显高于放疗前且差异均具有显著性。放疗后1个月、3个月的 DLCO%值明显低于放疗前,且放疗前的与放疗后3个月的差异具有显著性;V5≦45%、45%55%三组放疗前后的 FEV1%值和 FVC%值比较差异均不具有显著性。V5≦45%、45%55%三组放疗前后的 DLCO%值均呈逐渐下降趋势,且 V5>55%组的放疗前后 DLCO%值比较差异具有显著性。而 V5≦45%组和45%55%时,DLCO%值降低的趋势更加显著。 相似文献
9.
10.
《The ocular surface》2020,18(1):108-113
PurposeAromatase inhibitors (AIs) limit the synthesis of oestrogen in peripheral tissues thus lowering levels of oestrogen. The primary aim was to evaluate whether women treated with AIs have altered dry eye symptoms and signs. A sub-aim was to investigate whether symptoms of dry eye in postmenopausal women were associated with symptoms of non-eye pain, ocular pain and self-rated pain perception.MethodsThis cross-sectional, observational, single visit study recruited 56 postmenopausal women (mean age 64.1 + 7.9 years) and 52 undergoing AI treatment (mean age 66.6 + 9.0). Ocular symptoms (OSDI, MGD14) and pain questionnaires (PSQ, OPAS) were administered and signs of dry eye and meibomian gland dysfunction were evaluated.ResultsAlmost half of each group reported dry eye symptoms, defined as OSDI>12 (48% control, 46% AI). The PSQ score was significantly higher in the AI group (p = 0.04). Neither frequency or severity of dry eye (or MGD) symptoms scores were significantly different between groups. In the AI group, meibomian gland expressibility score was worse (p = 0.003); there were no differences in any other signs. Higher OSDI scores were associated with higher OPAS eye-pain scores (r = 0.49, p < 0.001), but not OPAS non-eye pain (r = 0.09, p = 0.35). Pain perception (PSQ) showed a moderate positive association with OPAS eye-pain (r = 0.30, p = 0.003).ConclusionsIn this study elevated ocular symptoms were observed in both the AI treated and the untreated groups, with no difference between the groups. Women undergoing AI treatment for early stage breast cancer had worse meibum expressibility score and increased pain perception compared to an untreated group of women. 相似文献